GSPT1 (G1 to S phase transition 1) is a crucial gene encoding eRF3a, a GTPase that partners with eRF1 to form the eukaryotic translation termination complex. The recurrent G575N mutation, a glycine-to-asparagine substitution at codon 575 within the GTP-binding domain, is a significant oncogenic driver in hematological malignancies, particularly acute myeloid leukemia (AML). This mutation profoundly impairs the GTP hydrolysis activity of eRF3a, leading to dysfunctional translation termination. Consequently, it results in widespread ribosome stalling and readthrough of stop codons. This disruption in protein synthesis promotes the stabilization of oncoproteins and genomic instability, thereby fueling leukemogenesis and cancer cell survival. The G575N mutant is clinically associated with aggressive disease progression, poorer overall survival, and resistance to conventional chemotherapy. Its pivotal role in oncogenesis has made it a compelling therapeutic target. Current research is intensely focused on developing targeted agents, such as cereblon E3 ligase modulators (e.g., CC-90009), which selectively degrade GSPT1 protein. These investigational drugs have shown promising pre-clinical efficacy, offering a potential novel strategy for treating AML patients harboring this high-risk mutation.